Sarah E. M. Herman

Statistics

Publications

Citations

6.4K

H-Index

Active since

1996

Affiliations

National Heart Lung and Blood Institute(Current)

National Institutes of Health

National Institutes of Health Clinical Center

National Cancer Institute

Center for Cancer Research

Sarah E. M. Herman is an author at National Heart Lung and Blood Institute specializing in oncology, medicine, and chronic lymphocytic leukemia therapy.

ORCID

Publications per year

1996–2022

Publications

Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765

Sarah E. M. Herman, Amber Gordon, Erin Hertlein et al. · Blood · 2011 · 791 citations · Full text

Medicine, Oncology, Pharmacology +15

CAL-101, a p110δ selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability

Brian J. Lannutti, Sarah Meadows, Sarah E. M. Herman et al. · Blood · 2010 · 718 citations · Full text

Medicine, Oncology, Pharmacology +11

Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals

Sarah E. M. Herman, Amber Gordon, Amy J. Wagner et al. · Blood · 2010 · 541 citations · Full text

Life Sciences, Oncology, Pharmacology +16

Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial

Mohammed Farooqui, Janet Valdez, Sabrina Martyr et al. · The Lancet Oncology · 2014 · 366 citations · Full text

Medicine, Immunology, Oncology +11

Clonal evolution leading to ibrutinib resistance in chronic lymphocytic leukemia

Inhye E. Ahn, Chingiz Underbayev, Adam Albitar et al. · Blood · 2017 · 342 citations · Full text

Medicine, Molecular Biology, Oncology +14

1–5 of 41